INS and Hypoglycemia: We found that for patients with type 2 diabetes, it seems that the addition of sulfonylurea to insulin (whether basal only or basal plus bolus) did not increase the risk of hypoglycemia-related ED and hospital care beyond what was observed for insulin alone.